Stem Cell as Tool for Drug Development
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 250
Special Issue Editors
Interests: neurodegenerative disorders; regenerative medicine; personalized medicine; disease modeling
2. Department of Neurology, University Hospitals Leuven, Leuven, Belgium
Interests: neuroimmunoloy; glial cell biology; neurodegenerative disorders; neuroimaging
Special Issue Information
Dear Colleagues,
The key changes for drug discovery are the lack of adequate model systems and compound-screening tools. With recent advances in the culturing and differentiation of induced pluripotent stem cells (iPSCs), it is now possible to study human disease-specific cell types to identify disease mechanisms and to develop large-scale screens for drug discovery. Specifically, the applications of using human-derived stem cells in drug discovery include the following: (1) it enables us to build up disease modeling from patients themselves; (2) it provides the basis for performing large-scale screens to find new drug targets; (3) the sophisticated 3D culture and organ-on-chip based on human iPSCs enable personalized diagnosis and drug testing. These advancements hold promise for the development of effective treatments that can diagnose disease onset early on, slow down disease progression, improve clinical symptoms, and ultimately provide hope for patients. One of the key challenges in developing effective drugs for neurodegenerative disorders is the lack of appropriate cellular models that accurately recapitulate the complexity of the human brain. This is where stem cells come into play. The use of stem cells in drug therapy for neurodegenerative disorders is important because it enables disease modeling, accelerates drug discovery, allows for personalized medicine approaches, provides insights into disease mechanisms, offers potential transplantation therapies, and ensures the safety of drug candidates. These advancements hold promise for the development of effective treatments that can slow disease progression, improve patient outcomes, and ultimately provide hope for individuals affected by neurodegenerative disorders.
Dr. Wenting Guo
Dr. Pegah Masrori
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- stem cells
- drug discovery
- modeling
- screens
- personalized medicine
